How mu-Opioid Receptor Recognizes Fentanyl.


Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
09 Sep 2020
Historique:
entrez: 16 9 2020
pubmed: 17 9 2020
medline: 17 9 2020
Statut: epublish

Résumé

The opioid crisis has escalated during the COVID-19 pandemic. More than half of the overdose-related deaths are related to synthetic opioids represented by fentanyl which is a potent agonist of mu-opioid receptor (mOR). In recent years, crystal structures of mOR complexed with morphine derivatives have been determined; however, structural basis of mOR activation by fentanyl-like synthetic opioids remains lacking. Exploiting the X-ray structure of mOR bound to a morphinan ligand and several state-of-the-art simulation techniques, including weighted ensemble and continuous constant pH molecular dynamics, we elucidated the detailed binding mechanism of fentanyl with mOR. Surprisingly, in addition to the orthosteric site common to morphinan opiates, fentanyl can move deeper and bind mOR through hydrogen bonding with a conserved histidine H297, which has been shown to modulate mOR's ligand affinity and pH dependence in mutagenesis experiments, but its precise role remains unclear. Intriguingly, the secondary binding mode is only accessible when H297 adopts a neutral HID tautomer. Alternative binding modes and involvement of tautomer states may represent general mechanisms in G protein-coupled receptor (GPCR)-ligand recognition. Our work provides a starting point for understanding mOR activation by fentanyl analogs that are emerging at a rapid pace and assisting the design of safer analgesics to combat the opioid crisis. Current protein simulation studies employ standard protonation and tautomer states; our work demonstrates the need to move beyond the practice to advance our understanding of protein-ligand recognition.

Identifiants

pubmed: 32935088
doi: 10.21203/rs.3.rs-67888/v1
pmc: PMC7491576
pii:
doi:

Types de publication

Preprint

Langues

eng

Commentaires et corrections

Type : UpdateIn

Références

Annu Rev Biophys. 2017 May 22;46:43-57
pubmed: 28301772
J Med Chem. 2000 Feb 10;43(3):381-91
pubmed: 10669565
J Chem Theory Comput. 2016 Nov 8;12(11):5411-5421
pubmed: 27709966
Neurosci Biobehav Rev. 2019 Nov;106:49-57
pubmed: 30528374
Br J Pharmacol. 2019 Dec;176(23):4510-4520
pubmed: 31355457
ACS Chem Neurosci. 2018 Oct 17;9(10):2428-2437
pubmed: 29894151
Future Med Chem. 2014 Mar;6(4):385-412
pubmed: 24635521
PLoS One. 2015 Aug 17;10(8):e0135998
pubmed: 26280453
Structure. 2018 Jan 2;26(1):171-180.e2
pubmed: 29249607
Nature. 2018 Jun;558(7711):547-552
pubmed: 29899455
Biophys J. 1996 Jan;70(1):97-110
pubmed: 8770190
J Pharm Pharmacol. 1988 Sep;40(9):605-8
pubmed: 2907025
Angew Chem Int Ed Engl. 2013 Sep 16;52(38):10112-5
pubmed: 23904331
J Biol Chem. 1994 Aug 12;269(32):20548-53
pubmed: 8051154
PLoS One. 2018 May 24;13(5):e0197734
pubmed: 29795628
Br J Pain. 2012 Feb;6(1):11-6
pubmed: 26516461
J Mol Model. 2019 May 3;25(5):144
pubmed: 31053968
Regul Toxicol Pharmacol. 2011 Apr;59(3):385-90
pubmed: 21215785
J Chem Theory Comput. 2011 Aug 9;7(8):2617-29
pubmed: 26606635
Nature. 2012 Mar 21;485(7398):321-6
pubmed: 22437502
Protein Sci. 2006 May;15(5):1214-8
pubmed: 16597822
J Neurochem. 1997 Jan;68(1):344-53
pubmed: 8978745
Brain Res Mol Brain Res. 2000 Mar 10;76(1):64-72
pubmed: 10719216
J Chem Theory Comput. 2011 Apr 12;7(4):1189-97
pubmed: 26606365
Nature. 2015 Aug 20;524(7565):315-21
pubmed: 26245379
J Chem Theory Comput. 2015 Feb 10;11(2):800-9
pubmed: 26392815
J Comput Chem. 2009 Jul 30;30(10):1545-614
pubmed: 19444816
Chem Sci. 2018 Jul 13;9(31):6480-6489
pubmed: 30310578
Nat Commun. 2016 Oct 06;7:12940
pubmed: 27708266
Eur J Pharmacol. 1992 Mar 24;213(2):219-25
pubmed: 1355735
Arzneimittelforschung. 1976;26(8):1548-51
pubmed: 12771
Proteins. 2011 Dec;79(12):3260-75
pubmed: 22002859
Trends Biochem Sci. 2014 May;39(5):233-44
pubmed: 24767681
Biochemistry. 2016 Nov 22;55(46):6456-6466
pubmed: 27778501

Auteurs

Quynh N Vo (QN)

Center for Drug Evaluation and Research, United State Food and Drug Administration, Silver Spring, Maryland 20993.
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201.

Paween Mahinthichaichan (P)

Center for Drug Evaluation and Research, United State Food and Drug Administration, Silver Spring, Maryland 20993.
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201.

Jana Shen (J)

Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201.

Christopher R Ellis (CR)

Center for Drug Evaluation and Research, United State Food and Drug Administration, Silver Spring, Maryland 20993.

Classifications MeSH